These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34196082)

  • 1. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care.
    Trevisan M; Fu EL; Xu Y; Savarese G; Dekker FW; Lund LH; Clase CM; Sjölander A; Carrero JJ
    Eur J Heart Fail; 2021 Oct; 23(10):1698-1707. PubMed ID: 34196082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.
    Trevisan M; de Deco P; Xu H; Evans M; Lindholm B; Bellocco R; Barany P; Jernberg T; Lund LH; Carrero JJ
    Eur J Heart Fail; 2018 Aug; 20(8):1217-1226. PubMed ID: 29667759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes.
    Xu Y; Fu EL; Trevisan M; Jernberg T; Sjölander A; Clase CM; Carrero JJ
    Am Heart J; 2022 Jan; 243():177-186. PubMed ID: 34610282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure.
    Henrysson J; Thunström E; Chen X; Fu M; Basic C
    ESC Heart Fail; 2023 Feb; 10(1):66-79. PubMed ID: 36161782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients.
    Clephas PRD; Radhoe SP; Linssen GCM; Langerveld J; Plomp J; Smits JPP; Nagelsmit MJ; Rocca HB; Brugts JJ
    ESC Heart Fail; 2023 Apr; 10(2):1481-1487. PubMed ID: 36738129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure.
    Allen LA; Shetterly SM; Peterson PN; Gurwitz JH; Smith DH; Brand DW; Fairclough DL; Rumsfeld JS; Masoudi FA; Magid DJ
    Circ Heart Fail; 2014 Jan; 7(1):43-50. PubMed ID: 24281136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with end-stage renal disease and heart failure.
    Lin DS; Lin FJ; Lin YS; Lee JK; Lin YH
    Eur J Heart Fail; 2023 Jan; 25(1):98-107. PubMed ID: 36404402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.
    Savarese G; Carrero JJ; Pitt B; Anker SD; Rosano GMC; Dahlström U; Lund LH
    Eur J Heart Fail; 2018 Sep; 20(9):1326-1334. PubMed ID: 29578280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.
    Mavrakanas TA; Giannetti N; Sapir-Pichhadze R; Alam A
    Cardiorenal Med; 2020; 10(1):32-41. PubMed ID: 31665724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Rossignol P; Lainscak M; Crespo-Leiro MG; Laroche C; Piepoli MF; Filippatos G; Rosano GMC; Savarese G; Anker SD; Seferovic PM; Ruschitzka F; Coats AJS; Mebazaa A; McDonagh T; Sahuquillo A; Penco M; Maggioni AP; Lund LH;
    Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study.
    Bruno N; Sinagra G; Paolillo S; Bonomi A; Corrà U; Piepoli M; Veglia F; Salvioni E; Lagioia R; Metra M; Limongelli G; Cattadori G; Scardovi AB; Carubelli V; Scrutino D; Badagliacca R; Guazzi M; Raimondo R; Gentile P; Magrì D; Correale M; Parati G; Re F; Cicoira M; Frigerio M; Bussotti M; Vignati C; Oliva F; Mezzani A; Vergaro G; Di Lenarda A; Passino C; Sciomer S; Pacileo G; Ricci R; Contini M; Apostolo A; Palermo P; Mapelli M; Carriere C; Clemenza F; Binno S; Belardinelli R; Lombardi C; Perrone Filardi P; Emdin M; Agostoni P
    ESC Heart Fail; 2018 Jun; 5(3):267-274. PubMed ID: 29397584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
    Ferreira JP; Zannad F; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Jamal W; Steubl D; Schueler E; Packer M
    J Am Coll Cardiol; 2021 Mar; 77(11):1397-1407. PubMed ID: 33736821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of developing hyperkalaemia in heart failure during long-term follow-up.
    Martens P; Kooij J; Maessen L; Dauw J; Dupont M; Mullens W
    Acta Cardiol; 2021 Aug; 76(6):589-597. PubMed ID: 32264757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Mineralocorticoid Receptor Antagonist Use With All-Cause Mortality and Hospital Readmission in Older Adults With Acute Decompensated Heart Failure.
    Yaku H; Kato T; Morimoto T; Inuzuka Y; Tamaki Y; Ozasa N; Yamamoto E; Yoshikawa Y; Kitai T; Taniguchi R; Iguchi M; Kato M; Takahashi M; Jinnai T; Ikeda T; Nagao K; Kawai T; Komasa A; Nishikawa R; Kawase Y; Morinaga T; Toyofuku M; Seko Y; Furukawa Y; Nakagawa Y; Ando K; Kadota K; Shizuta S; Ono K; Sato Y; Kuwahara K; Kimura T;
    JAMA Netw Open; 2019 Jun; 2(6):e195892. PubMed ID: 31225889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor antagonist use following heart failure hospitalization.
    Duran JM; Gad S; Brann A; Greenberg B
    ESC Heart Fail; 2020 Apr; 7(2):482-492. PubMed ID: 32035000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative mineralocorticoid receptor antagonist reduces postoperative hyperkalaemia in patients with Conn syndrome.
    Zhang J; Libianto R; Lee JC; Grodski S; Shen J; Fuller PJ; Yang J
    Clin Endocrinol (Oxf); 2022 Jan; 96(1):40-46. PubMed ID: 34743353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter regarding the article 'Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care'.
    Alexandrou ME; Sarafidis PA
    Eur J Heart Fail; 2022 Feb; 24(2):399. PubMed ID: 34816543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.